Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Vanguard Total International Bond Index Fund ETF (BNDX) vs BioNano Genomics Inc (BNGO) Price & Performance

Vanguard Total International Bond Index Fund ETFTrade
BioNano Genomics IncTrade

Price performance (Past 24H)

Key statistics

Vanguard Total International Bond Index Fund ETF vs BioNano Genomics Inc — how do they compare? Vanguard Total International Bond Index Fund ETF trades at $47.81, while BioNano Genomics Inc trades at $1.18 (market cap $13.66M). Which is the better fit depends on your goals.

BNDXBNGO
52-Week High
$49.91$4.92
52-Week Low
$47.57$1.06
Market Cap
$13.66M
Sector
Health
Enterprise Value
$16.26M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Vanguard Total International Bond Index Fund ETF

BNDX trades at $47.82, up 0.06% on the day, amid a bearish technical signal with moving averages indicating selling pressure and oscillators neutral. Recent news highlights institutional activity, including Apella Capital reducing its stake and Archer Investment Management increasing holdings. The fund's dividend schedule shows consistent payouts, with the latest dividend of $0.12 scheduled for payment in August 2026.

The outlook for BNDX is cautious due to bearish technical indicators and mixed institutional sentiment. Risks include interest rate volatility and inflation concerns, as highlighted by recent Treasury yield movements. Opportunities lie in its role as a bond ETF providing diversified international fixed income exposure, but investors should weigh macroeconomic factors affecting bond markets.

BioNano Genomics Inc

BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.

The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.

Returns comparison

Trailing returns across standard periods

About Vanguard Total International Bond Index Fund ETF

The fund employs an indexing investment approach designed to track the performance of the Bloomberg Global Aggregate ex-USD Float Adjusted RIC Capped Index (USD Hedged). This index provides a broad-based measure of the global, investment-grade, fixed-rate debt markets. It is non-diversified.

Read more on BNDX

About BioNano Genomics Inc

Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.

Read more on BNGO